TWi Gets FDA Approval for Generic Megace ES, Launch Held up by Patent Appeal

Drug Industry Daily
A A
Taiwan-based TWi Pharmaceuticals has won final FDA approval for a generic version of Par Pharmaceutical’s AIDS drug Megace ES, but the product’s launch remains on hold as the brandmaker appeals its 2011 patent infringement lawsuit.

To View This Article:

Login

Subscribe To Drug Industry Daily